BBL
AZN icon

Beck Bode LLC’s AstraZeneca AZN Stock Holding History

Beck Bode LLC’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-111,772
Closed -$17.2M – 96
2025
Q3 		$17.2M Buy
111,772
+3,555
+3% +$538K 2.77% 19
2025
Q2 		$15.1M Buy
+108,217
New +$15.2M 2.56% 23
2023
Q2 		– Sell
-39,552
Closed -$5.49M – 142
2023
Q1 		$5.49M Sell
39,552
-1,720
-4% -$231K 1.35% 21
2022
Q4 		$5.6M Buy
+41,272
New +$5.18M 1.26% 27
2021
Q3 		– Sell
-250
Closed -$30K – 98
2021
Q2 		$30K Sell
250
-1,801
-88% -$198K 0.01% 164
2021
Q1 		$204K Buy
+2,051
New +$206K 0.06% 68
2020
Q4 		– Sell
-1,371
Closed -$150K – 28
2020
Q3 		$150K Buy
+1,371
New +$152K 0.05% 63

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Beck Bode LLC's AZN Position: Q4 2025 in Review

Beck Bode LLC sold out of AstraZeneca (AZN) in Q4 2025, closing a stake of 111,772 shares — an estimated $17.2M sold.

Beck Bode LLC first reported a position in AZN in Q3 2020 and held it in 7 quarters. The position peaked at $17.2M in Q3 2025. 1,406 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

  • Beck Bode LLC reported no remaining AstraZeneca position as of Q4 2025 after selling out during the quarter.
  • Beck Bode LLC sold 111,772 AstraZeneca shares in Q4 2025, an estimated $17.2M.
  • Beck Bode LLC first reported a position in AstraZeneca in Q3 2020 and held it in 7 quarters.
  • Beck Bode LLC's AstraZeneca position peaked at $17.2M in Q3 2025.
  • 1,406 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on Beck Bode LLC's 13F filing for Q4 2025, filed 9 Feb 2026.